Spots Global Cancer Trial Database for Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer
Official Title: A Phase II Study of Tesetaxel Administered at a Flat Dose Once Every 21 Days as Second-line Therapy to Subjects With Advanced Gastric Cancer
Study ID: NCT01095120
Interventions
Study Description
Brief Summary: Tesetaxel is an orally administered chemotherapy agent of the taxane class. This study is being undertaken to evaluate the efficacy and safety of tesetaxel administered as second-line therapy to patients with advanced gastric cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Northwestern Medical Faculty Foundation, Chicago, Illinois, United States
Abramson Cancer of the University of Pennsylvania at Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
The University of Texax MD Anderson Cancer Center, Houston, Texas, United States
Severance Hospital, Yonsei University Health System, Seoul, , Korea, Republic of
Contact Details
Name: Jaffer Ajani, MD
Affiliation: The University of Texas MD Anderson Cancer Center
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
